^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Meiyouheng (becotatug vedotin)

    i
    Other names: MRG003, MRG-003, MRG 003
    Company:
    Lepu Med
    Drug class:
    Microtubule inhibitor, EGFR-targeted antibody-drug conjugate
    Related drugs:
    2d
    A Randomized, Open-Label, Exploratory Phase II Clinical Study of MRG003 in Combination with Anti-EGFR Monoclonal Antibody and Pucotenlimab versus Investigator's Choice of Treatment in Patients with EGFR-Positive Esophageal Squamous Cell Carcinoma Who Failed First-Line Standard Therapy (ChiCTR2600121404)
    P=N/A, N=74, Zhejiang Provincial People's Hospital; Zhejiang Provincial People's Hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR positive
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    2d
    Becotatug Vedotin Combined with Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer (ChiCTR2600121010)
    P2, N=31, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
    |
    MSI-H/dMMR • BRAF mutation • RAS wild-type
    |
    Erbitux (cetuximab) • Meiyouheng (becotatug vedotin)
    2d
    The Efficacy and Safety of Becotatug Vedotin and Pucotenlimab as Neoadjuvant Therapy in Locally Advanced Laryngeal Cancer (IGNITE-Larynx) (ChiCTR2600120886)
    P2, N=55, Eye & ENT Hospital, Fudan University; Department of Otorhinolaryngology Head and Neck Surgery
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    2d
    A phase II clinical study to evaluate the efficacy and safety of MRG003 (Becotatug Vedotin) as a monotherapy or in combination with bevacizumab in the treatment of EGFR-positive platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. (ChiCTR2600120503)
    P2, N=54, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial • Platinum resistant
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    Avastin (bevacizumab) • Meiyouheng (becotatug vedotin)
    2d
    Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC) (clinicaltrials.gov)
    P2, N=26, Not yet recruiting, Shanghai Zhongshan Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    PD-L1 expression • EGFR expression
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    2d
    A single-center, double-cohort, open-label clinical trial evaluating the safety and efficacy of vebecotota monoclonal antibody for injection, either in combination or alone with putrilimab injection, in patients with recurrent or metastatic salivary gland cancer (ChiCTR2600118473)
    P2, N=90, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    EGFR expression
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    4d
    Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=40, Recruiting, Fudan University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor)
    |
    Meiyouheng (becotatug vedotin)
    4d
    ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P1/2, N=41, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P1/2 trial
    |
    Meiyouheng (becotatug vedotin) • Qibeian (iparomlimab/tuvonralimab)
    7d
    Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Fudan University
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    Meiyouheng (becotatug vedotin)
    9d
    Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2 (clinicaltrials.gov)
    P2, N=93, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    cisplatin • Tevimbra (tislelizumab-jsgr) • Meiyouheng (becotatug vedotin)
    11d
    Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=430, Recruiting, Ming-Yuan Chen
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR positive
    |
    cisplatin • Meiyouheng (becotatug vedotin)
    11d
    MRG003-SACC: A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Eye & ENT Hospital of Fudan University
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    epirubicin • Meiyouheng (becotatug vedotin)